Compare ADMA Biologics Inc (ADMA) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Docusign Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Docusign Inc trades at $57.85 (market cap $11.33B). The key difference: Docusign Inc is far larger — about 5.1× ADMA Biologics Inc's market cap, and Docusign Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DOCU | |
|---|---|---|
Market Cap | $2.22B | $11.33B |
Sector | Health | Technology |
52-Week High | $20.38 | $85.01 |
52-Week Low | $7.60 | $41.75 |
Enterprise Value | $2.29B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DOCU trades at $59.64, down 1.03% today but maintaining strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $2.8B in 2024 to $3.0B in 2025 and impressive net income margin expansion to 35.87%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.09 surpassing the $0.994 estimate. Institutional activity shows mixed signals with some funds reducing positions while others increase exposure.
DOCU presents a compelling growth story with strong profitability metrics and consistent earnings beats, though valuation remains elevated at 38.53 P/E. The stock faces near-term resistance at $60-$62 levels with overbought RSI conditions. Analyst consensus leans cautious with 67.86% hold ratings, suggesting potential consolidation before further upside. Key risks include competitive pressures in e-signature space and execution challenges in maintaining current growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
